Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 14/20 | 0.60 |
| ▸ | KDR | P35968 | 6/20 | 0.60 |
| ▸ | SRC | P12931 | 3/20 | 0.60 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.60 |
| ▸ | AXL | P30530 | 3/20 | 0.60 |
| ▸ | FLT3 | P36888 | 3/20 | 0.60 |
| ▸ | MST1R | Q04912 | 3/20 | 0.60 |
| ▸ | KIT | P10721 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 2/20 | 0.53 |
| ▸ | LCK | P06239 | 2/20 | 0.53 |
| ▸ | FYN | P06241 | 2/20 | 0.53 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.53 |
| ▸ | LTK | P29376 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | YES1 | P07947 | 1/20 | 0.53 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
| ▸ | INPPL1 | O15357 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104578 | 0.91 | MET (0.49) | METKDRSRCFGFR2AXL | |
| SCHEMBL3109645 | 0.91 | CYP3A4 (0.53) | METKDRSRCFGFR2AXL | |
| SCHEMBL3112523 | 0.89 | CYP3A4 (0.49) | METKDRSRCFGFR2AXL | |
| SCHEMBL3093043 | 0.86 | CYP3A4 (0.48) | METKDRSRCFGFR2AXL | |
| SCHEMBL3102102 | 0.85 | CYP3A4 (0.55) | METKDRSRCFGFR2AXL | |
| SCHEMBL3104670 | 0.84 | MET (0.53) | METKDRSRCFGFR2AXL | |
| SCHEMBL3110496 | 0.84 | MET (0.53) | METKDRSRCFGFR2AXL | |
| SCHEMBL3107120 | 0.84 | CYP3A4 (0.53) | METKDRSRCAXLCYP1A2 | |
| SCHEMBL3098969 | 0.83 | MET (0.51) | METKDRSRCFGFR2AXL | |
| SCHEMBL3099104 | 0.82 | CYP3A4 (0.55) | AXLCYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188078-B2 | 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20100273793-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-10-28 | — | — | US | disclosed |
| EP-2205568-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009087305-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS | SANOFI-AVENTIS (FR) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273793-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS | MET, ALK, JAK2 | MET 1/4885KDR 41/4885SRC 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.